TUSTIN, Calif., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing...
Leverages Established Track Record of Excellence in Biologics CGMP Manufacturing to Address the Rapidly Growing Cell and Gene Therapy Market World-Class...
Accomplished Senior Executive with Nearly 30 Years of Sales Experience Spanning CDMO Offerings, Clinical Development Services and Scientific Products...
-- Recorded First Quarter Revenue of $30.8 Million --
TUSTIN, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives...
TUSTIN, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives...
Former SVP of Global Manufacturing at Biogen Has Nearly 30 Years of Biopharmaceutical Industry Experience
-- Recorded Fourth Quarter Revenue of $27.6 Million and Annual Revenue of $95.9 Million --
TUSTIN, Calif., June 22, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives...
ZYNLONTA™ Recently Approved as First and Only CD19-Targeted Antibody Drug Conjugate for Single-Agent Treatment for Adult Patients with Relapsed or Refractory (r/r) Diffuse Large B-cell Lymphoma (DLBCL)...